Tempest Therapeutics (FRA:3OS0) Inventories, Raw Materials & Components: €0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:3OS0 Tempest Therapeutics Inc FRA:3OS0
31 GF Score
Price €5.82
! 1 Warning Sign
View Full Analysis

What is Tempest Therapeutics Inventories, Raw Materials & Components?

Tempest Therapeutics FRA:3OS0 31 Inventories, Raw Materials & Components is €0.00 Mil as of Jun. 2026. GuruFocus rates FRA:3OS0 with a GF Score™ of 31/100. The stock has 1 warning sign investors should review.

Tempest Therapeutics's inventories, raw materials & components for the quarter that ended in Jun. 2026 was €0.00 Mil.

Tempest Therapeutics Inventories, Raw Materials & Components Historical Data

* Premium members only.

The historical data trend for Tempest Therapeutics's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tempest Therapeutics Inventories, Raw Materials & Components Chart

Tempest Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Raw Materials & Components
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Tempest Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:3OS0
31GF Score
Tempest Therapeutics Inc FRA:3OS0
Inventories, Raw Materials & Components is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tempest Therapeutics Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

What does a Inventories, Raw Materials & Components of €0.00 Mil mean?
Tempest Therapeutics (FRA:3OS0) has a Inventories, Raw Materials & Components of €0.00 Mil as of Jun. 2026. Raw materials are the components a company uses for its main products. View historical data on Tempest Therapeutics and its competitors.
Is Tempest Therapeutics' Inventories, Raw Materials & Components too high?
Tempest Therapeutics' current Inventories, Raw Materials & Components is €0.00 Mil. Overall, Tempest Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Tempest Therapeutics' Inventories, Raw Materials & Components compare to ICU and INTI?
Tempest Therapeutics' Inventories, Raw Materials & Components of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Biotechnology company?
A good Inventories, Raw Materials & Components depends on the Biotechnology industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on Tempest Therapeutics and its competitors. Tempest Therapeutics's current Inventories, Raw Materials & Components is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tempest Therapeutics stock overvalued right now?
Tempest Therapeutics (FRA:3OS0) has a current Inventories, Raw Materials & Components of €0.00 Mil. The current Inventories, Raw Materials & Components is €0.00 Mil. Tempest Therapeutics' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For Tempest Therapeutics (FRA:3OS0), the current Inventories, Raw Materials & Components is €0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tempest Therapeutics Business Description

Other Exchanges TPST:USA
Address 2000 Sierra Point Parkway, Suite 400, Brisbane, CA, USA, 94005
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
31GF Score

Get the complete analysis for FRA:3OS0

Inventories, Raw Materials & Components is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.82
Price